Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Apr;111(4):1205–1211. doi: 10.1111/j.1476-5381.1994.tb14873.x

Effect of a 5-lipoxygenase inhibitor, ZM 230487, on cutaneous allergic inflammation in the guinea-pig.

M M Teixeira 1, P G Hellewell 1
PMCID: PMC1910165  PMID: 8032607

Abstract

1. Leukotrienes have potent biological effects in vitro and in vivo and are found in tissue and in biological fluids in various pathological conditions including allergic diseases. Leukotriene B4 (LTB4) is a potent stimulus for eosinophil accumulation and activation and there is much interest in determining its importance in mediating the accumulation of eosinophils at sites of allergic inflammation in vivo. In this study, we investigated the effects of a potent 5-lipoxygenase inhibitor, ZM 230487, on the accumulation of eosinophils and on local oedema formation in cutaneous inflammation in the guinea-pig. 2. The i.d. injection of increasing concentrations of arachidonic acid (AA) led to a dose-dependent accumulation of 111In-eosinophils but oedema formation was only significant at the top dose of AA tested (3 x 10(-8) mol per site). Co-injection of ZM 230487 with AA inhibited 111In-eosinophil accumulation up to 99% but the small oedema response to AA was only partially inhibited. AA-induced oedema formation was only effectively inhibited when a combination of a PAF antagonist, an antihistamine and ZM 230487 was used. 3. Local administration of the cyclo-oxygenase inhibitor, ibuprofen, partially inhibited AA-induced oedema formation suggesting that vasodilator prostaglandins may be released following i.d. injection of AA. AA-induced 111In-eosinophil accumulation was also partially inhibited by ibuprofen. 4. PAF-induced 111In-eosinophil accumulation was partially suppressed by local administration of ZM 230487. In contrast, LTB4-induced 111In-eosinophil accumulation was enhanced by ZM 230487. These data suggest that locally-released leukotrienes may modulate mediator-induced eosinophil accumulation. ZM 230487 had no effect on PAF- or LTB4-induced oedema formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1205

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aked D. M., Foster S. J. Leukotriene B4 and prostaglandin E2 mediate the inflammatory response of rabbit skin to intradermal arachidonic acid. Br J Pharmacol. 1987 Nov;92(3):545–552. doi: 10.1111/j.1476-5381.1987.tb11355.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aked D., Foster S. J., Howarth A., McCormick M. E., Potts H. C. The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation. Br J Pharmacol. 1986 Oct;89(2):431–438. doi: 10.1111/j.1476-5381.1986.tb10277.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson G. P., Fennessy M. R. Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. Agents Actions Suppl. 1988;23:195–200. doi: 10.1007/978-3-0348-9156-1_14. [DOI] [PubMed] [Google Scholar]
  4. Barr R. M., Brain S., Camp R. D., Cilliers J., Greaves M. W., Mallet A. I., Misch K. Levels of arachidonic acid and its metabolites in the skin in human allergic and irritant contact dermatitis. Br J Dermatol. 1984 Jul;111(1):23–28. doi: 10.1111/j.1365-2133.1984.tb04012.x. [DOI] [PubMed] [Google Scholar]
  5. Batt D. G. 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem. 1992;29:1–63. doi: 10.1016/s0079-6468(08)70004-3. [DOI] [PubMed] [Google Scholar]
  6. Brain S. D., Crossman D. C., Buckley T. L., Williams T. J. Endothelin-1: demonstration of potent effects on the microcirculation of humans and other species. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S147–S150. [PubMed] [Google Scholar]
  7. Bray M. A. Leukotrienes in inflammation. Agents Actions. 1986 Oct;19(1-2):87–99. doi: 10.1007/BF01977263. [DOI] [PubMed] [Google Scholar]
  8. Busse W. W., Gaddy J. N. The role of leukotriene antagonists and inhibitors in the treatment of airway disease. Am Rev Respir Dis. 1991 May;143(5 Pt 2):S103–S107. doi: 10.1164/ajrccm/143.5_Pt_2.S103. [DOI] [PubMed] [Google Scholar]
  9. Cheng J. B. Early efficacy data with a newer generation of LTD4 antagonists in antiasthma trials: early promise for a single mediator antagonist. Pulm Pharmacol. 1992 Jun;5(2):77–80. doi: 10.1016/0952-0600(92)90023-a. [DOI] [PubMed] [Google Scholar]
  10. Collins P. D., Weg V. B., Faccioli L. H., Watson M. L., Moqbel R., Williams T. J. Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo. Immunology. 1993 Jun;79(2):312–318. [PMC free article] [PubMed] [Google Scholar]
  11. Coëffier E., Joseph D., Vargaftig B. B. LTB4, a potent chemotactic factor for purified guinea-pig eosinophils: interference of PAF-acether antagonists. Int J Immunopharmacol. 1991;13(2-3):273–280. doi: 10.1016/0192-0561(91)90108-j. [DOI] [PubMed] [Google Scholar]
  12. Crawley G. C., Briggs M. T., Dowell R. I., Edwards P. N., Hamilton P. M., Kingston J. F., Oldham K., Waterson D., Whalley D. P. 4-Methoxy-2-methyltetrahydropyrans: chiral leukotriene biosynthesis inhibitors, related to ICI D2138, which display enantioselectivity. J Med Chem. 1993 Jan 22;36(2):295–296. doi: 10.1021/jm00054a016. [DOI] [PubMed] [Google Scholar]
  13. Czarnetzki B. M., Mertensmeier R. In vitro and in vivo chemotaxis of guinea pig leukocytes toward leukotriene B4 and its w-oxidation products. Prostaglandins. 1985 Jul;30(1):5–11. doi: 10.1016/s0090-6980(85)80006-x. [DOI] [PubMed] [Google Scholar]
  14. Davidson E. M., Rae S. A., Smith M. J. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis. 1983 Dec;42(6):677–679. doi: 10.1136/ard.42.6.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Djukanović R., Roche W. R., Wilson J. W., Beasley C. R., Twentyman O. P., Howarth R. H., Holgate S. T. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990 Aug;142(2):434–457. doi: 10.1164/ajrccm/142.2.434. [DOI] [PubMed] [Google Scholar]
  16. Emery D. L., Djokic T. D., Graf P. D., Nadel J. A. Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol (1985) 1989 Sep;67(3):959–962. doi: 10.1152/jappl.1989.67.3.959. [DOI] [PubMed] [Google Scholar]
  17. Faccioli L. H., Nourshargh S., Moqbel R., Williams F. M., Sehmi R., Kay A. B., Williams T. J. The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo. Immunology. 1991 Jun;73(2):222–227. [PMC free article] [PubMed] [Google Scholar]
  18. Hidi R., Coëffier E., Vargaftig B. B. Formation of LTB4 by fMLP-stimulated alveolar macrophages accounts for eosinophil migration in vitro. J Leukoc Biol. 1992 May;51(5):425–431. doi: 10.1002/jlb.51.5.425. [DOI] [PubMed] [Google Scholar]
  19. Hirata K., Maghni K., Borgeat P., Sirois P. Guinea pig alveolar eosinophils and macrophages produce leukotriene B4 but no peptido-leukotriene. J Immunol. 1990 Mar 1;144(5):1880–1885. [PubMed] [Google Scholar]
  20. Hui K. P., Barnes N. C. Inhibition of leukotriene synthesis: new therapy in asthma? Pulm Pharmacol. 1993 Mar;6(1):3–9. doi: 10.1006/pulp.1993.1002. [DOI] [PubMed] [Google Scholar]
  21. Ishida K., Thomson R. J., Schellenberg R. R. Role of leukotrienes in airway hyperresponsiveness in guinea-pigs. Br J Pharmacol. 1993 Mar;108(3):700–704. doi: 10.1111/j.1476-5381.1993.tb12864.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kauffman H. F., van der Belt B., de Monchy J. G., Boelens H., Koëter G. H., de Vries K. Leukotriene C4 production by normal-density and low-density eosinophils of atopic individuals and other patients with eosinophilia. J Allergy Clin Immunol. 1987 Apr;79(4):611–619. doi: 10.1016/s0091-6749(87)80157-4. [DOI] [PubMed] [Google Scholar]
  23. Kidney J. C., Ridge S. M., Chung K. F., Barnes P. J. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 1993 Jan;147(1):215–217. doi: 10.1164/ajrccm/147.1.215. [DOI] [PubMed] [Google Scholar]
  24. Kroegel C., Chilvers E. R., Giembycz M. A., Challiss R. A., Barnes P. J. Platelet-activating factor stimulates a rapid accumulation of inositol (1,4,5)trisphosphate in guinea pig eosinophils: relationship to calcium mobilization and degranulation. J Allergy Clin Immunol. 1991 Jul;88(1):114–124. doi: 10.1016/0091-6749(91)90308-b. [DOI] [PubMed] [Google Scholar]
  25. Lam S., Chan H., LeRiche J. C., Chan-Yeung M., Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 1988 Apr;81(4):711–717. doi: 10.1016/0091-6749(88)91043-3. [DOI] [PubMed] [Google Scholar]
  26. Makker H. K., Lau L. C., Thomson H. W., Binks S. M., Holgate S. T. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1413–1418. doi: 10.1164/ajrccm/147.6_Pt_1.1413. [DOI] [PubMed] [Google Scholar]
  27. McMillan R. M., Bird T. G., Crawley G. C., Edwards M. P., Girodeau J. M., Kingston J. F., Foster S. J. Methoxyalkyl thiazoles: a novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase. Agents Actions. 1991 Sep;34(1-2):110–112. doi: 10.1007/BF01993252. [DOI] [PubMed] [Google Scholar]
  28. McMillan R. M., Spruce K. E., Crawley G. C., Walker E. R., Foster S. J. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br J Pharmacol. 1992 Dec;107(4):1042–1047. doi: 10.1111/j.1476-5381.1992.tb13404.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. McMillan R. M., Walker E. R. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci. 1992 Aug;13(8):323–330. doi: 10.1016/0165-6147(92)90100-k. [DOI] [PubMed] [Google Scholar]
  30. Musser J. H., Kreft A. F. 5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors. J Med Chem. 1992 Jul 10;35(14):2501–2524. doi: 10.1021/jm00092a001. [DOI] [PubMed] [Google Scholar]
  31. Nielsen V. G., Webster R. O. Inhibition of human polymorphonuclear leukocyte functions by ibuprofen. Immunopharmacology. 1987 Feb;13(1):61–71. doi: 10.1016/0162-3109(87)90027-0. [DOI] [PubMed] [Google Scholar]
  32. O'Shaughnessy K. M., Taylor I. K., O'Connor B., O'Connell F., Thomson H., Dollery C. T. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1431–1435. doi: 10.1164/ajrccm/147.6_Pt_1.1431. [DOI] [PubMed] [Google Scholar]
  33. Piacentini G. L., Kaliner M. A. The potential roles of leukotrienes in bronchial asthma. Am Rev Respir Dis. 1991 May;143(5 Pt 2):S96–S99. doi: 10.1164/ajrccm/143.5_Pt_2.S96. [DOI] [PubMed] [Google Scholar]
  34. Pradalier A. Late-phase reaction in asthma: basic mechanisms. Int Arch Allergy Immunol. 1993;101(3):322–325. doi: 10.1159/000236471. [DOI] [PubMed] [Google Scholar]
  35. Richards I. M., Sun F. F., Taylor B. M., Shields S. K., Griffin R. L., Morris J., Wishka D. G., Smith H. W., Johnson R. A., Dunn C. J. Contribution of leukotriene B4 to airway inflammation and the effect of antagonists. Ann N Y Acad Sci. 1991;629:274–287. doi: 10.1111/j.1749-6632.1991.tb37983.x. [DOI] [PubMed] [Google Scholar]
  36. Salmon J. A., Garland L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog Drug Res. 1991;37:9–90. doi: 10.1007/978-3-0348-7139-6_1. [DOI] [PubMed] [Google Scholar]
  37. Sehmi R., Cromwell O., Taylor G. W., Kay A. B. Identification of guinea pig eosinophil chemotactic factor of anaphylaxis as leukotriene B4 and 8(S),15(S)-dihydroxy-5,9,11,13(Z,E,Z,E)-eicosatetraenoic acid. J Immunol. 1991 Oct 1;147(7):2276–2283. [PubMed] [Google Scholar]
  38. Spada C. S., Woodward D. F., Hawley S. B., Nieves A. L. Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins. 1986 Apr;31(4):795–809. doi: 10.1016/0090-6980(86)90181-4. [DOI] [PubMed] [Google Scholar]
  39. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  40. Teixeira M. M., Williams T. J., Hellewell P. G. E-type prostaglandins enhance local oedema formation and neutrophil accumulation but suppress eosinophil accumulation in guinea-pig skin. Br J Pharmacol. 1993 Sep;110(1):416–422. doi: 10.1111/j.1476-5381.1993.tb13826.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Teixeira M. M., Williams T. J., Hellewell P. G. Role of prostaglandins and nitric oxide in acute inflammatory reactions in guinea-pig skin. Br J Pharmacol. 1993 Dec;110(4):1515–1521. doi: 10.1111/j.1476-5381.1993.tb13994.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ueno A., Tanaka K., Katori M., Hayashi M., Arai Y. Species difference in increased vascular permeability by synthetic leukotriene C4 and D4. Prostaglandins. 1981 Apr;21(4):637–648. doi: 10.1016/0090-6980(81)90012-5. [DOI] [PubMed] [Google Scholar]
  43. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  44. Wardlaw A. J., Moqbel R., Cromwell O., Kay A. B. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest. 1986 Dec;78(6):1701–1706. doi: 10.1172/JCI112765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Weg V. B., Watson M. L., Cordeiro R. S., Williams T. J. Histamine, leukotriene D4 and platelet-activating factor in guinea pig passive cutaneous anaphylaxis. Eur J Pharmacol. 1991 Nov 5;204(2):157–163. doi: 10.1016/0014-2999(91)90700-z. [DOI] [PubMed] [Google Scholar]
  46. Weg V. B., Williams T. J., Lobb R. R., Nourshargh S. A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med. 1993 Feb 1;177(2):561–566. doi: 10.1084/jem.177.2.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wenzel S. E., Larsen G. L., Johnston K., Voelkel N. F., Westcott J. Y. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990 Jul;142(1):112–119. doi: 10.1164/ajrccm/142.1.112. [DOI] [PubMed] [Google Scholar]
  48. Williams T. J., Peck M. J. Role of prostaglandin-mediated vasodilatation in inflammation. Nature. 1977 Dec 8;270(5637):530–532. doi: 10.1038/270530a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES